NASHVILLE, Tenn., Sept. 27, 2018 /PRNewswire/ -- Cumberland
Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty
pharmaceutical company and Clinigen Group plc (AIM: CLIN,
'Clinigen'), the global pharmaceutical and services company,
announce a new publication in Lung Cancer: Targets and
Therapy of a contemporary retrospective series showing that
subcutaneous amifostine administered before radiotherapy postponed
the onset of acute esophagitis in stage 3 small cell lung cancer
patients treated with concomitant doublet chemotherapy and
hyperfractionated radiotherapy.
Cumberland markets branded
amifostine in the U.S territory under the name Ethyol®
on behalf of Clinigen Group plc who is the market authorization
holder and owner of global rights.
Concurrent chemoradiotherapy, delivered every three weeks in
conjunction with radiotherapy, is recognized as a standard
treatment option in patients with stage 3 small cell lung
carcinoma. Acute esophageal inflammation has been described as a
dose-limiting effect and is observed in ~25% of patients undergoing
such treatment. Studies have reported a relationship between the
volume of the esophagus irradiated and the likelihood of an acute
injury. Series have reported volumes of esophagus irradiated as
most reflective of acute symptoms.
The study, led by Ariel E Pollock M.D, Icahn School of Medicine
at Mt. Sinai, New York, evaluated
the impact of amifostine on protecting the esophagus. Its aim was
to determine if the amifostine group experienced less weight loss,
less use of opiates during treatment, and/or allowed for a higher
dose of radiotherapy to be delivered before opioids were needed for
symptomatic relief of acute esophagitis. They assessed stage 3
small cell lung cancer patients treated at the Schiffler Cancer
Center in Wheeling Hospital West Virginia between 2005 and 2016.
Chemotherapy consisted of cisplatin and etoposide, with
radiotherapy twice daily. In 32 patients (group 1), amifostine was
delivered prior to the second daily radiotherapy treatment. The
remaining 17 patients (group 2) did not receive amifostine.
The study investigators concluded, based on their observations
and objective measurements, that subcutaneous amifostine may
postpone the onset of acute esophagitis in a subset of patients
with small cell lung carcinoma receiving concurrent
chemoradiotherapy.
About Ethyol® (amifostine)
Ethyol is indicated to reduce the cumulative renal toxicity
associated with repeated administration of cisplatin in patients
with advanced ovarian cancer. It is indicated to reduce the
incidence of moderate to severe xerostomia in patients undergoing
post-operative radiation treatment for head and neck cancer, where
the radiation port includes a substantial portion of the parotid
glands. Xerostomia, or diminished saliva production, can lead to
difficulties eating, speaking, and swallowing. Ethyol is
contraindicated in patients with known hypersensitivity to
aminothiol compounds.
For full prescribing and important safety information, please
visit www.ethyol.com.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical
company focused on the delivery of high-quality prescription brands
to improve patient care. The Company develops, acquires, and
commercializes brands for the hospital acute care,
gastroenterology, and oncology market segments.
For more information, please visit www.cumberlandpharma.com.
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing ethical access to medicines. Its mission is to deliver
the right medicine to the right patient at the right time through
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines.
For more information, please visit www.clinigengroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/newly-published-data-demonstrates-amifostine-delayed-the-onset-of-acute-esophagitis-for-small-cell-lung-cancer-patients-300720169.html
SOURCE Cumberland Pharmaceuticals Inc.